HA‐NEDD4‐1 OE, but not the enzyme‐dead NEDD4‐1‐C867S mutant, sensitized MM cells to Bor, suggesting that an NEDD4‐1 enzymatic activator may be proposed as a novel targeted therapy to overcome the Bor resistance mediated by low NEDD4‐1 activity. This evidence concerns the gene NEDD4 and Miyoshi myopathy.